A fluorescent plasmonic biochip assay for multiplex screening of diagnostic serum antibody targets in human Lyme disease.

ABSTRACT: Lyme disease (LD) diagnosis using the current two-tier algorithm is constrained by low sensitivity for early-stage infection and ambiguity in determining treatment response. We recently developed a protein microarray biochip that measures diagnostic serum antibody targets using grating-coupled fluorescent plasmonics (GC-FP) technology. This strategy requires microliters of blood serum to enable multiplexed biomarker screening on a compact surface and generates quantitative results that can be further processed for diagnostic scoring. The GC-FP biochip was used to detect serum antibodies in patients with active and convalescent LD, as well as various negative controls. We hypothesized that the quantitative, high-sensitivity attributes of the GC-FP approach permit: 1) screening of antibody t

SUBMITTER: Chou E 

PROVIDER: S-EPMC7010292 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature